Alloy Therapeutics
Boston, United States · Biotechnology · 119 employees
Alloy Therapeutics is a biotechnology ecosystem company empowering the global scientific community to make better medicines together. From licensing our platforms, to working with us as a trusted discovery service partner, we have collaborated with over 170+ partners and counting including 18 of Fortune 50 Biopharmaceutical companies to enable the discovery of their next breakthrough biologic med
Funding history
- Series series e — $40.0M — Apr 2026
- Funding Round — $2.7M — Jan 2025
- Funding Round — $41.7M — Oct 2022
- Series series d — $42.0M — Oct 2022
- Funding Round — $75.0M — Apr 2021
Recent signals
- May 05, 2026: Alloy Therapeutics and Institute for Protein Innovation Forge Partnership to Enhance Antibody Discovery
- Apr 15, 2026: Raised $40.0M in Series series e
- Jan 06, 2026: Alloy Therapeutics Appoints Christian Cobaugh as Chief Executive Officer
- Oct 23, 2025: Acquired Alloy Therapeutics acquires Spannerwerks for growth
- Jan 30, 2025: Raised $2.7M
- Nov 21, 2024: Takeda and Alloy Therapeutics partner to accelerate advanced cancer therapies using stem cell technology
- Nov 20, 2024: Launched Alloy Therapeutics Inc. announces collaboration with Takeda to enhance iCAR-T and iCAR-NK cell therapy platforms.
- Oct 30, 2024: Alloy Therapeutics enters institutional licensing agreement with Scripps Research for ATX-Gx™ Platform
See plans & pricing → Track Alloy Therapeutics’s funding, hiring, and signals — with verified contacts — on Fundz.